(61a) Minipharm: A Miniaturized Pharmaceutical Manufacturing Platform for Process Development
- Conference: AIChE Spring Meeting and Global Congress on Process Safety
- Year: 2019
- Proceeding: 2019 Spring Meeting and 15th Global Congress on Process Safety
- Group: Process Development Division
- Time: Tuesday, April 2, 2019 - 8:00am-8:30am
The compound selected in this study was Diphenhydramine hydrochloride (DPH). The reaction consists of a single step and has been shown as an example of atom economy due to the direct synthesis of the final product without the necessity of an extraction/solvent swap step. The reaction provided an opportunity for development of the platform with a molecule that is suitable for continuous small-scale production. Platform development included individual unit operation characterization and the coupled unit operation screening prior to the complete design integration. Initial unit operation studies provided valuable insight into system parameters necessary for system integration.
The implementation of PAT was critical from the start of platform development. Monitoring of the module performance was achieved with the use of Ultra high performance liquid chromatography (UPLC) and Mass Spectrometry. Characterization of crystal products was carried out using powder x-ray diffraction (XRD) and Raman spectroscopy. Imaging of the crystallization process in segmented flow was monitored by using an optical camera. Crystal morphology and size distribution data was measured using Malvern Morphologi G3. Reactor module development consisted of a screening multiple residences at various temperatures to determine product concentration. Initial extraction development focused on pH adjustment for product recovery; however, Thin Layer Chromatography (TLC) results provided insight into a non-pH adjusted approach to isolate DPH. Crystallization module development began with cooling only crystallization, but was expanded to include a combined anti-solvent and cooling approach to allow for enhanced product recovery.
In this study, the development of an integrated, reconfigurable platform was detailed for Diphenhydramine hydrochloride process development. PAT tools were used to determine the performance of unit operations in the integrated system. Finally, products from the simultaneous purification routes were compared to determine the effectiveness of additional purification steps on the final product purity. Implementation of the process development framework in a multi-step reaction will be explored in future studies.